Clinical Study Notes: Prostatitis and Benign Prostatic Hyperplasia (BPH)

Prostatitis: Classifications and Epidemiology

• Prostatitis is a complex condition involving the prostate gland, traditionally grouped into four distinct syndromes:   - Acute bacterial prostatitis: An acute infection of the prostate.   - Chronic bacterial prostatitis: A persistent infection often resulting from inadequate eradication.   - Chronic pelvic pain syndrome (CPPS): A condition characterized by long-term pelvic pain; it can be difficult to provide relief for these patients.   - Asymptomatic prostatitis: Prostatitis diagnosed without the presence of symptoms.
• Prevalence and Statistics:   - Approximately $5\%$ of ambulatory care visits involve men reporting genitourinary symptoms.   - Approximately $2,000,000$ visits annually result in a diagnosis of prostatitis.   - It is a common diagnosis in acute care settings.

Clinical Presentation and Assessment of Prostatitis

• Acute Bacterial Prostatitis:   - Patients typically appear clinically ill ("they look sick and they are sick").   - Symptoms include:     - Fever and chills.     - Lower back pain.     - Dysuria.     - Inability to empty the bladder.     - Painful ejaculation.     - Malaise.   - Physical Assessment Results:     - Large, tender, and swollen prostate due to the presence of cytokines and immune cells.     - The prostate may feel firm and warm to the touch.
• Chronic Bacterial Prostatitis:   - Presents with more subtle infection indicators and symptoms.
• Chronic Pelvic Pain Syndrome Assessment:   - Symptoms localized in the perineal or lower abdominal area.   - Evidence of inflammation or inflammatory changes in the prostate with abnormal findings.   - Pain or discomfort derived from or associated with the prostate and the lower urinary tract.   - Symptoms may be inducible after a particular cause with varying incubation times.
• Risk Factors for Prostatitis:   - Anything increasing the risk for genitourinary (GU) infection.   - Use of catheters.   - History of diabetes.   - Immunocompromised status.

Pathophysiology of Prostatitis

• Acute Prostatitis Pathophysiology:   - Driven by an inflammatory immune response.   - Infectious Origin: $E. coli$ is the most common cause, accounting for $50\% \text{ to } 90\%$ of cases. Other bacteria are also involved but less frequently.
• Chronic Prostatitis Pathophysiology:   - Typically involves "sequestered bacteria."   - This occurs when antibiotics fail to eradicate the initial infection, as the prostate can be a difficult organ for medications to penetrate.
• Nonbacterial Prostatitis Theories:   - Urethral Reflux: Relaxation of the urinary sphincter and disordered voiding causing urine to reflex into the prostate, triggering a sterile inflammatory response.   - Neurological Factors: Increased pelvic autonomic activity leading to the development of pain circuits similar to other chronic pain disorders, occurring even in the absence of inflammatory findings.

Evaluation and Diagnosis of Prostatitis

• Standard Procedures:   - Examination of the prostate.   - Collection of urine cultures.
• Systemic Studies: If the patient appears severely ill, clinicians should obtain a Complete Blood Count (CBC) and Basic Metabolic Panel (BNP).
• Prostate Massage:   - Used to identify bacteria specifically in the prostate.   - Warning: Do not perform a prostate massage in the presence of acute bacterial prostatitis, as it can aggravate the infection and potentially make it systemic (sepsis).
• Specialized Diagnostic Tools:   - Clinical scoring systems.   - Transrectal ultrasonography (TRUS).

Treatment and Complications of Prostatitis

• Bacterial Treatment: Requires antibiotics.
• Chronic Bacterial Treatment: Referral to a specialist and long durations of antibiotic therapy.
• Chronic Prostatitis/CPPS Multi-modal Treatment:   - Anti-inflammatories.   - Antidepressants.   - Hormonal therapy.   - Pelvic floor physical therapy.   - Myofascial trigger point therapy.
• Complications:   - Bacterial prostatitis can lead to sepsis.   - CPPS significantly impacts quality of life, affecting the ability to work and leading to negative psychological outcomes.
• Takeaway Point: Prostatitis can be acute, chronic, or poorly understood (CPPS). It is characterized by irritative/obstructive urinary symptoms, urogenital diaphragm muscle spasm, and perineal pain.

Benign Prostatic Hyperplasia (BPH): Definition and Epidemiology

• Definition: Non-malignant adenomatous overgrowth of the periurethral prostate gland.
• Prevalence Statistics (via Autopsy Data):   - Ages $31 \text{ to } 40$: $8\%$ of males.   - Ages $51 \text{ to } 60$: $40\% \text{ to } 50\%$ of males.   - Age $> 80$: Greater than $80\%$ of males.
• BPH is extremely common as men age.

Clinical Presentation of BPH

• Symptoms:   - Urinary frequency.   - Urgency.   - Nocturia (e.g., waking up $3$ times per night to urinate).   - Urinary hesitancy.   - "Stutter start" (interrupted) stream during urination.
• Primary Risk Factor: Aging.

Pathophysiology and Mechanisms of BPH

• Nodule Formation: Multiple fibroadenomatous nodules develop in the periurethral region, likely originating from the periurethral glands.
• Urethral Obstruction: The prostate wraps around the urethra; as it grows, the prostatic urethra narrows and lengthens.
• Theories of Causation:   - Changes in estrogen and androgen ratios due to aging.   - Chronic inflammation and paracrine growth stimulation.   - Suppression of growth-inhibiting factors.   - Circulating androgens disrupting the balance between growth stimulation and inhibition.
• Hormonal Conversion: Testosterone is converted to Dihydrotestosterone (DHT) via the enzyme 5\text{-\alpha reductase}.
• Remodeling Processes: Inflammation and interleukin mediators remodel the stroma, leading to increased cell growth, angiogenesis, and fibroblast activity.
• Histology: The glands feature a bilayered structure of epithelial columnar and cuboidal cells, eventually causing a flattening of the muscular stroma.

Evaluation and Management of BPH

• Diagnostic Assessment:   - BPH scoring systems to evaluate symptom severity.   - Digital Rectal Exam (DRE) to assess the prostate.   - Urinalysis and urine culture.   - Prostate-Specific Antigen (PSA) level.   - Bladder ultrasound.
• Pharmacological Treatment:   - Alpha Blockers: Used to relax the tissues in the urinary tract.   - Contraindicated Medications: Avoid anticholinergics, sympathomimetics, and opioids, as these can increase urinary retention.
• Complications of BPH:   - Prolonged urinary retention.   - Bilateral hydronephrosis leading to renal disease.   - High risk for urinary tract infections (UTIs) and secondary prostatitis.
• Surgical Intervention: Treatment may advance to surgery if pharmacological management is insufficient.
• Takeaway Point: BPH is a very common condition. Clinicians must understand the physiology of alpha receptors in the urinary tract to avoid administering medications (anticholinergics, sympathomimetics, opioids) that worsen urinary symptoms.